Vaxxas

Vaxxas Pty Ltd is a clinical-stage biotechnology company based in Brisbane, Queensland, Australia.

Founded in 2011 as a spin-out from the Australian Institute of Bioengineering and Nanotechnology at the University of Queensland, Vaxxas focuses on innovative vaccine delivery solutions. The company employs around 130 people and operates a pilot-scale manufacturing facility in Brisbane, with additional offices in the United States. Vaxxas is known for its proprietary High-Density Microarray Patch (HD-MAP) technology, marketed as the NanopatchTM. This needle-free patch delivers vaccines directly to the skin's immune cells, enhancing immune responses while reducing the required vaccine dosage. The technology also simplifies logistics by eliminating the need for refrigeration. Vaxxas collaborates with major pharmaceutical companies, government agencies, and global organizations to advance its mission of improving vaccine access and effectiveness, particularly in infectious diseases and oncology. The company has secured significant funding to support its growth and commercialization efforts.